Organon (OGN) Non-Current Assets (2020 - 2026)
Organon (OGN) posted quarterly Non-Current Assets of $8.1 billion for Q1 2026, down 8.21% year-over-year from $8.8 billion in Q1 2025, and down 5.3% on a QoQ basis from $8.5 billion in Q4 2025.
Organon (OGN) Non-Current Assets (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Non-Current Assets for 7 consecutive years, with $8.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 8.21% year-over-year to $8.1 billion; the TTM figure through Mar 2026 stood at $34.3 billion (up 3.42% YoY), while the FY2025 annual figure was $8.5 billion, down 2.72% from the prior year.
- Non-Current Assets came in at $8.1 billion for Q1 2026 at Organon, down from $8.5 billion in the prior quarter.
- The five-year high for Non-Current Assets was $8.9 billion in Q2 2025, with the low at $6.8 billion in Q2 2022.
- Average Non-Current Assets over 5 years is $7.7 billion, with a median of $7.6 billion recorded in 2024.
- Across the five-year window, Non-Current Assets advanced 16.18% in 2025 and decreased 8.21% in 2026, its largest moves.
- Year by year, Non-Current Assets stood at $7.0 billion in 2022, then grew by 7.49% to $7.6 billion in 2023, then advanced by 15.93% to $8.8 billion in 2024, then dropped by 2.72% to $8.5 billion in 2025, then slipped by 5.3% to $8.1 billion in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $8.1 billion, $8.5 billion, and $8.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 61.74 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 141.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 102.93 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 84.40 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 8.06 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.06 Bn |
| Dec 31, 2025 | 8.52 Bn |
| Sep 30, 2025 | 8.85 Bn |
| Jun 30, 2025 | 8.88 Bn |
| Mar 31, 2025 | 8.79 Bn |
| Dec 31, 2024 | 8.75 Bn |
| Sep 30, 2024 | 8.00 Bn |
| Jun 30, 2024 | 7.65 Bn |
| Mar 31, 2024 | 7.70 Bn |
| Dec 31, 2023 | 7.55 Bn |
| Sep 30, 2023 | 6.96 Bn |
| Jun 30, 2023 | 7.02 Bn |
| Mar 31, 2023 | 6.98 Bn |
| Dec 31, 2022 | 7.02 Bn |
| Sep 30, 2022 | 6.85 Bn |
| Jun 30, 2022 | 6.84 Bn |
| Mar 31, 2022 | 6.88 Bn |
| Dec 31, 2021 | 6.92 Bn |
| Sep 30, 2021 | 7.01 Bn |
| Jun 30, 2021 | 7.00 Bn |